Therapy News and Research

RSS

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC).

14 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

12 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Early treatment significantly reduces joint damage in rheumatoid arthritis

Early and consistently managed treatment can have a decisive impact on the course of rheumatoid arthritis and prevent permanent joint damage.

11 Sep 2026

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults

11 Sep 2026

Early studies hint that ketones may affect pathways linked to PTSD

An integrative review found that ketogenic therapy may influence metabolic, inflammatory, oxidative stress, and neurotransmitter pathways implicated in PTSD, with animal studies and small human studies reporting early signs of symptom improvement. Human evidence remains limited to very small cohorts, case reports, and pilot studies, and controlled trials have yet to establish clinical efficacy.

11 Sep 2026

Laser therapy offers new hope for inoperable pancreatic tumors

UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, phase 1 clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become cancer free.

10 Sep 2026

Avoiding antibody-dependent enhancement enables dengue prevention and treatment

Dengue virus is one of the most widespread vector-borne viral pathogens in the world. Nearly 400 million dengue virus infections occur each year, resulting in approximately 20,000 deaths.

10 Sep 2026

Breast cancer AI test finds no single chatbot excels across every measure

Researchers compared five large language models on breast cancer health information using 90 knowledge questions, 10 clinical cases, and 20 common patient concerns, with all prompts submitted in simplified Chinese. The models performed strongly on standardized knowledge overall, but differed in linguistic complexity and expert-rated completeness, readability, helpfulness, correctness, and safety.

10 Sep 2026

Chronic interferon exposure drives immunosuppression in tumors

Cancer biology and, in turn, cancer treatment have come a long way in the last few decades. Most people recognize this progress in breakthroughs like immunotherapy-a treatment strategy first deployed in 2011 that leverages the body's own immune cells to fight cancer and revolutionized the treatment landscape.

10 Sep 2026

New treatment approach preserves organs, improves survival in head and neck cancer patients

Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors responded to neoadjuvant immunochemotherapy (ICT) and who underwent less extensive surgery had high disease-free survival and organ preservation rates.

10 Sep 2026

Study reveals processes driving DNA damage in prostate cancer

Cancer begins with errors in the DNA inside our cells, and those errors are often more complicated than a handful of mutated genes.

9 Sep 2026

Previous
1
...
17
18
19
20
21
22
23
...
2953
Next

Therapy News and Research

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Low discontinuation rates confirm manageable safety of iza-bren

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

Early treatment significantly reduces joint damage in rheumatoid arthritis

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Early studies hint that ketones may affect pathways linked to PTSD

Laser therapy offers new hope for inoperable pancreatic tumors

Avoiding antibody-dependent enhancement enables dengue prevention and treatment

Breast cancer AI test finds no single chatbot excels across every measure

Chronic interferon exposure drives immunosuppression in tumors

New treatment approach preserves organs, improves survival in head and neck cancer patients

Study reveals processes driving DNA damage in prostate cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News